Stockreport
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 [Seeking Alpha]
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Key catalysts include VISTAS topline data in Q2 2026, VANTAGE topline data in H1 2027, and phase 3 EXPAND enrollment completion in 2026. Company strengthened its balance sheet with $200M gross proceeds from Bluejay Therapeutics acquisition and private placements, plus a $68.5M TCGX placement agreement. MIRM risks include pivotal trial outcomes, regulatory approvals, and integration of Bluejay's brelovitug HDV program, with topline AZURE data expected in H2 2026. SeventyFour/iStock via Getty Images The last time I spoke about Mirum Pharmaceuticals, Inc. ( MIRM ) it was in a Seeking Alpha article entitled "Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value." With respect to this article, I More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-wee
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So [Seeking Alpha][Seeking Alpha]
- Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Citizens Jmp from $95.00 to $140.00. They now have a "market outperform" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX[Business Wire]
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..[MarketBeat]
- More
MIRM
SEC Filings
SEC Filings
- 12/22/25 - Form 144
- 12/19/25 - Form 4
- 12/19/25 - Form 144
- MIRM's page on the SEC website
- More